trx103
Cell therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 8, 2024 (NCT06462365)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Crohn Disease · Phase 1/Phase 2
- Graft vs Host Disease · Phase 1
- Hematologic Neoplasms · Phase 1
- Hematopoietic Stem Cell Transplantation · Phase 1
- Leukemia-Lymphoma, Adult T-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Myelodysplastic Syndromes · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Remission Induction · Phase 1
Mechanism of action
- T cellSupplementation
T cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06721962 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2024 | Tr1X, Inc. |
| NCT06462365 | Phase 1 | Apr 8, 2024 | Tr1X, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tr1X, Inc. | For profit | 2 | 2 | 2 | 2024 |
1 organizations
Page 1 / 1